SCHEMBL24316428

SCHEMBL24316428

COc1ccc(COc2ccc(Oc3ccc4ncc(C)c(=O)n4c3)cn2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.39
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
GRM5 P41594 3/20 0.37
PDE1A P54750 4/20 0.36
PDE1B Q01064 4/20 0.36
PDE1C Q14123 4/20 0.36
PDE2A O00408 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
CLK1 P49759 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
CASP3 P42574 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24316432 0.91 ACACB (0.37) ALKBH1ACACBACACAGRM5ALDH1A1
SCHEMBL24316659 0.88 ALKBH1 (0.40) ALKBH1GRM5PDE1APDE1BPDE1C
SCHEMBL24316436 0.88 KDM4E (0.37) GRM5KDM4EALDH1A1NPC1RAB9A
SCHEMBL24316545 0.85 CSF1R (0.43) ALKBH1GRM5PDE1APDE1BPDE1C
SCHEMBL24316434 0.84 CSF1R (0.53) ALKBH1GRM5PDE1APDE1BPDE1C
SCHEMBL24316438 0.83 GRM5 (0.43) GRM5
SCHEMBL24316565 0.83 CSF1R (0.44) ALKBH1GRM5PDE1APDE1BPDE1C
SCHEMBL24316660 0.81 CSF1R (0.40) ALKBH1GRM5KDM4EALDH1A1PKM
SCHEMBL24316982 0.79 CSF1R (0.48) ALKBH1GRM5KDM4EALDH1A1PKM
SCHEMBL24316623 0.79 P2RX3 (0.39) ALKBH1GRM5KDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092774-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2024-03-21 US disclosed
WO-2022057895-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-03-24 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092774-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF CYP2D6, CYP3A7, CYP2F1 ALKBH1 2069/4885ACACB 1762/4885ACACA 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.